Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Completed · Phase 1

Conditions studied: Influenza

In brief

This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA) followed by licensed 2012/2013 TIV vaccine. The comparator groups will receive licensed 2012/2013 TIV as prime and boost. The hypothesis is that the 2012/2013 HA DNA prime-TIV boost regimen will be safe and result in a broader and more durable immune response than is observed in age-matched comparator TIV-TIV groups.

Key facts

Study ID: NCT01609998
Run by: National Institute of Allergy and Infectious Diseases (NIAID)
People needed: 75
Starts: 2012-06-01
Expected to finish: 2013-07-01
Last updated by the study team: 2018-12-06

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Children/adolescents aged 6 to 17 years inclusive and at least 20 kg in weight.
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
Willing to have blood drawn 5 times over 42 weeks, including blood stored for research purposes.
In good general health as assessed by medical history, vital signs and targeted physical examination; stable medical conditions that, in the opinion of the investigator, will not compromise the subject's participation in the study are acceptable.
Capability of the legal adult representative of the minor to understand and comply with planned study procedures.
Capability of the legal adult representative of the minor to provide written informed consent; assent will be obtained from the child/adolescent per requirements of the site institutional review board (IRB).
For female adolescent of child-bearing potential (as defined by onset of menses): agrees to avoid becoming pregnant and to use effective method of contraception or practice abstinence for at least 21 day prior to the first study vaccine administration, until at least 4 weeks after the second study vaccination.
Within 70 days prior to enrollment, hemoglobin within institutional normal limits, creatinine less than the upper limit of normal (ULN) and ALT ≤1.5 X ULN for respective age group.

You may not qualify if…

History of Guillain-Barré syndrome.
Active neoplasm or history of cancer.
On-going immunosuppressive therapy or known to be immunosuppressed at the time of enrollment.
Immunoglobulin (or similar blood product) therapy within 3 months prior to enrollment.
Known to have HIV, hepatitis B or hepatitis C infection.
Acute or chronic illness that, in the opinion of the investigator, precludes participation in the study.
Developmental delay, neurologic disorder, or seizure disorder requiring ongoing medical management (note: history of febrile seizure is not an exclusion).
Acute febrile and/or respiratory illness within one week prior to enrollment.
Idiopathic urticaria within the year prior to enrollment.
Allergy treatment with antigen injections, unless on maintenance schedule and allergy shots could be staggered with the study vaccinations, within 14 days (2 weeks) prior to enrollment.
Asthma that is severe, unstable or required emergent care, urgent care, hospitalization or intubation during the previous two years or that is expected to require the use of oral, intravenous or high dose inhaled corticosteroids.
Vaccination of any type within 2 weeks prior to enrollment or receipt of the 2012/2013 seasonal TIV any time prior to enrollment.
Participating in or planning to begin participation in another investigational study during the projected time during which the subject would be in this study.
Factors related to the legal representative that in the judgment of the investigator may affect the objective decision-making of the legal representative.
For a female adolescent of child-bearing potential: breast-feeding, known pregnancy or positive urine or serum pregnancy test on day of study enrollment.

Where it is running

Emory Children's Center — Atlanta, Georgia, United States
Saint Louis University - Doisy Research Center — St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States
The Gamble Program for Clinical Studies, Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.